



Press Release

Louvain-la-Neuve, Belgium and Lalaye, France – April 25, 2024

## RADIOPHARMACEUTICALS MARKET EXPERIENCING A SURGE IN M&A ACTIVITY

In March, AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals (USA) a clinical stage company focused on developing novel radiotherapeutics for the treatment of cancer. After Bristol-Myers Squibb acquired RayzeBio (USA) and Eli Lilly acquired POINT Biopharma (USA) in December 2023, followed by Icon Infrastructure Partners' acquisition of Alliance Medical Group in January 2024, this marks the fourth significant M&A transaction in the radiopharmaceutical industry within the last five months, amounting to a total of US\$ 9 billion.

This trend underscores the growing interest of the pharmaceutical industry with radiopharmaceuticals.

The radiopharmaceutical sector presents abundant opportunities, offering various avenues for larger corporations or investors to support these advancements and potentially engage in collaborations with strategic partners through mergers and acquisitions. These opportunities extend beyond diagnostic radiopharmaceuticals. The pipelines for radiotherapeutic development reveal a substantial number of products that could potentially hit the market by 2028.

There are multiple openings for larger corporations or investors to fund these developments and potentially collaborate with strategic partners through M&A.

If you would like to find your next partners or M&A targets, the **MEDraysintell Nuclear Medicine Report & Directory Edition 2023** is a must read, comprising three volumes that provide a comprehensive and complete overview of the nuclear medicine landscape worldwide. The report provides a comprehensive and exhaustive review of the radiopharmaceutical sector, encompassing 1,070 products, including radionuclides, radiodiagnostic agents, and radiotherapeutics, along with in-depth profiles of 410 dedicated companies. This information is presented across three volumes (Marketed, Clinical and Early-Stage Radiopharmaceuticals), spanning more than 3,700 pages.

Additionally, a database containing all the clinical and early-stage radiopharmaceuticals described in the reports can also be provided to assist users in their research.

***To request a detailed table of contents and sample pages, please contact Paul-Emmanuel Goethals at [peg@medraysintell.com](mailto:peg@medraysintell.com)***

Click [HERE](#) to access a presentation with key insights on Nuclear Medicine and new drugs to come.

### About MEDraysintell

MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, cyclotron, proton therapy and brachytherapy. We offer the most comprehensive set of reports and directories, with almost 4,900 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts.

We are proud to support numerous companies globally, helping them to better understand the markets, the competitive environment as well as the potential of merger and acquisitions (M&A) and technology development. We have repeated satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and university research laboratories.

MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. The team brings together more than 50 years of expertise in the field of radiation healthcare. [www.medraysintell.com](http://www.medraysintell.com)

### Contact

**Paul-Emmanuel Goethals**, MBA  
Louvain-la-Neuve, Belgium  
e-Mail: [peg@medraysintell.com](mailto:peg@medraysintell.com)  
Mobile: +32 491 080 968

**Richard Zimmermann**, PhD  
Lalaye, France  
e-Mail: [rz@medraysintell.com](mailto:rz@medraysintell.com)  
Mobile: +33 6 82 80 06 00